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It is well known that neuronal damage following a stroke has been attributed to the over stimulation of excitatory
amino acids such as glutamate and aspartate through activation of NMDA receptors. The brain is exposed to most
of the constituents of plasma including homocysteine as a result of the disruption of the blood–brain barrier after
stroke, head trauma and stress. The question, therefore, arises as to whether or not homocysteine is able to
selectively stimulate the release of excitatory amino acids in stroke. This review article will address the importance
of homocysteine in nervous system specifically how these amino acids may trigger the release of catecholamines.
Our data will thus strengthen the view that a mechanism for the association of hyperhomocysteinemia with
increased brain lesion in stroke. As hypothalamus also controls the cardiac function via sympathetic system, the
contractility of heart will be compromised. Homocysteine is also known to mediate cardiovascular problems by its
adverse effects on cardiovascular endothelium and smooth muscle cells with resultant alterations in subclinical
arterial structure and function. The present review will thus summarize both central and peripheral effects of
homocysteine and will highlight some of the controversies associated with hyperhomocysteinemia-induced
cardiovascular problems.Introduction
Homocysteine has been under a lot of speculation since
its discovery in 1932. Its chemical properties showed a
similarity to cysteine, hence the name homocysteine.
The heating of the amino acid methionine with
sulphuric acid led to this amino acid of interest. The
importance of this discovery cannot be emphasized on
without alluding to the 1955 Nobel Prize in Chemistry,
awarded to Vincent du Vigneaud “For his work on
biochemically important sulphur compounds, especially
for the first synthesis of a polypeptide hormone” [1].
Recent years have shown a dramatic increase in research
towards the better understanding of the notoriety of this
amino acid of interest (Figure 1).
Homocysteine, a sulfhydryl-containing amino acid, is
an intermediate product in the normal biosynthesis of
the amino acids methionine and cysteine [2]. It is an
amino acid produced via demethylation of dietary
methionine, which is abundant in animal protein [3]. It
is present in plasma in four different forms: around 1%* Correspondence: pganguly@alfaisal.edu
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unless otherwise stated.circulates as free thiol, 70–80% remains disulphide-
bound to plasma proteins, mainly albumin and 20–30%
combines with itself to form the dimer homocysteine or
with other thiols [4]. Homocysteine is a key determinant
of the methylation cycle [5]. It is methylated to methio-
nine, which undergoes S-adenosylation and forms S-
adenosylmethionine (SAM) [5]. S- adenosylmethionine
is the principal methyl donor for all methylation reac-
tions in cells [5]. Condensation of methionine with ATP,
leads to the formation of SAM (S- Adenosylmethionine)
[6]. The methyl group attached to the tertiary sulphur of
SAM can be transferred and therefore can cause methy-
lation of other substances. This methylation is accom-
panied by energy loss, so this reaction is irreversible.
The demethyation reaction leads to the formation of
SAH (S- adenosylhomocysteine) [6]. SAH is a thioether
(a sulfur bonded to two alkyl or aryl groups) analogous
to methionine. The SAM-to-SAH ratio defines the
methylation potential of a cell [5]. Hydrolysis of SAH
leads to the formation of homocysteine and adenosine
[6]. This homocysteine can be used in one of two ways:
a) In case of methionine deficiency, homocysteine can
be re-methylated to form methionine [6]. Theentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Structure of homocysteine.
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reductase converts homocysteine to methionine [2].
b) In presence of sufficient methionine, homocysteine
is instead used to produce cysteine [6].
Cystathionine-β-synthase is an enzyme (with
pyridoxine (vitamin B6) as an essential cofactor) that
converts homocysteine to cysteine [2]. Homocysteine is
synthesized from the essential amino acid methionine,
therefore cysteine is not an essential amino acid as long
as sufficient methionine is available [6].
Biochemical basis of hyperhomocysteinemia
While the present analysis will provide an insight into
cause-and-effect of hyperhomocysteinemia and cardio-
vascular diseases, the potential role of nutritional homo-
cysteine are great and the readers are referred to other
articles dealing with nutritional therapies for managing
homocysteine.
The definition of hyperhomocysteinemia differs between
studies [2]. Hyperhomocysteinemia is defined as a medical
condition characterized by an abnormally high level
(above 15 μmol/L) of homocysteine in the blood [7]. Total
concentration of homocysteine in plasma of healthy
humans (fasting) is low and its level is between 5.0 and
15.0 μmol/L when assessed with the use of HPLC, or
5.0-12.0 μmol/l when immunoassay methods are used [8].
When the level is between 16-30 μmol/L it is classified as
moderate, 31-100 μmol/L is considered intermediate and a
value above 100 μmol/L is classified as severe hyperhomo-
cysteinemia [4]. There are two types of hyperhomocysteine-
mia: (1) the rare but severe forms are due to major genetic
mutations of the enzymes implicated in homocysteine
metabolism; (2) the more common forms cause moderately
elevated homocysteine levels related to a pathogenesis such
as genetic and environmental factors [2].
Hyperhomocysteinemia may arise from genetic defects
of enzymes involved in homocysteine metabolism. The
enzymes involved can be 5, 10-methylene tetrahydrofo-
late reductase, methionine synthase, and cystathionine-
β-synthase [9]. The most common one that is detectedworldwide and has a high incidence in different popula-
tions, is single nucleotide polymorphisms of 5,10-methy-
lene tetrahydrofolate reductase which has been associated
with mild (13–24 μM) and moderate (25–60 μM) hyper-
homocysteinemia [9]. Hankey et al. [4] stated that the
most common enzyme defect associated with moderately
raised total homocysteine is a point mutation (C-to-T
substitution at nucleotide 677) in the coding region of the
gene for MTHFR, which is associated with a thermo labile
MTHFR variant that has about half-normal activity [4]. The
most common of the genetic causes of severe hyperhomo-
cysteinemia and classic homocystinuria (congenital homo-
cystinuria) is believed to be homozygous deficiency of CβS
(cystathionine-β-synthase) which results in an increase of up
to 40-fold in fasting total homocysteine. Other rarer causes
of severe hyperhomocysteinemia are considered to be homo
zygous deficiency of MTHFR, deficiency of methionine
synthase, and impaired activity of methionine synthase due
to genetic disorders of vitamin B12 metabolism [4].
Hyperhomocysteinemia can also arise from nutritional
deficiencies of folate, vitamin B6, and vitamin B12 [9].
Blood levels of folate, vitamin B12 and to a lesser extent,
vitamin B6 are related inversely to total homocysteine;
therefore a person with a nutritional deficiency that leads
to low blood concentrations of the aforementioned is at
increased risk of hyperhomocysteinemia [4,9]. Several
diseases such as renal and thyroid dysfunction, cancer,
psoriasis, and diabetes as well as various drugs, alcohol,
tobacco, coffee, older age and menopause, are believed to
be associated with moderately elevated homocysteine
concentrations [2]. A rise in serum creatinine also leads to
a rise in fasting total homocysteine [4]. The major route of
homocysteine clearance from plasma is the kidney, and
the rise is due to defective metabolism of homocysteine by
the kidney [4]. Total homocysteine levels are found to be
considerably higher in patients with chronic renal disease
than the moderately raised concentrations commonly
found in patients with atherothrombotic vascular disease,
and this may be the probable cause that contributes to the
high incidence of vascular complications in patients with
chronic renal failure [4]. Plasma homocysteine concentra-
tions can be increased by various drugs and diseases that
interfere with folate, vitamin B6, and B12 metabolism, hence
an abnormal homocysteine concentration may have a prob-
able use as a diagnostic aid for some of these conditions [4].
There has been an indication towards a significant cor-
relation between hyperhomocysteinemia and cardiovascu-
lar disease and its complications such as heart attacks and
strokes [8]. It is believed that hyperhomocysteinemia leads
to endothelial cell damage, reduction in the flexibility of
vessels, and alters the process of haemostasis [8]. Hyper-
homocysteinemia may lead to an enhancement of the
adverse effects of risk factors like hypertension, smoking,
lipid and lipoprotein metabolism, as well as promotion of
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hyperhomocysteinemia may vary significantly between
populations, and most likely depend on age, diet, and
genetic background as well [2]. Increasing age, male sex,
smoking, coffee consumption, high blood pressure,
unfavourable lipid profile, high creatinine and faulty diet
are some of the factors associated with increased homo-
cysteine levels [10]. On the other hand, physical activity,
moderate alcohol consumption, good folate and vitamin
B12 status are associated with lower homocysteine levels.
Vegetarians may be at a higher risk of hyperhomocystei-
nemia due to low plasma B12 levels but the difference is
likely to be insignificant [10].
The SAM-to-SAH ratio defines the methylation poten-
tial of a cell as mentioned before. Hyperhomocysteinemic
states tend to decrease this ratio, leading to decreased
methylation potential [5]. There is some evidence that
indicates that homocysteine can lead to global DNA hypo-
methylation. It may also suppress transcription of cyclin A
in endothelial cells [5]. This is a gene-specific effect. In the
core promoter, it causes demethylation of a CpG site and
this eliminates the binding of methyl CpG-binding protein
2. This in turn, limits HDAC (Histone deacetylases) bind-
ing. Therefore this causes acetylated H3 and H4 histones
to accumulate and to suppress gene expression [5]. DNA
hypomethylation and histone acetylation are associated
with transcriptional permissive chromatin [5]. The open
conformation of chromatin may allow increased access by
repressor proteins, leading to transcriptional suppression.
To account for changes in apoA-1 and apoA-IV in
hyperhomocysteinemia, similar epigenetic regulatory mech-
anisms have been reported [5]. On the contrary, homo
cysteine-induced DNA hypomethylation of their promoters
causes some genes to be up regulated, for example, the
homocysteine induction increases p66shc expression in
endothelial cells, and this correlates with promoter hypo-
methylation thus contributing to oxidant stress [5].
The homocysteine and the nervous system
In the last decade, epidemiological observations have
pointed towards a plausible association between hyperho-
mocysteinemia and CNS neurodegenerative disorders.
Several studies demonstrated that homocysteine is capable
of triggering neuronal damage via oxidative stress, DNA
damage and activation of pro-apoptotic factors in cell cul-
tures or animal models [9]. In an experiment, SH-SY5Y
neuroblastoma cells were modified to act as neuronal
cells, by incubating them with retinoic acid, which in-
duced their differentiation towards a neuronal-like pheno-
type [9]. This was followed by incubation with/without D,
L-homocysteine in a concentration range from 20 μM to
80 μM [9]. The exposure to homocysteine induced a time
and concentration dependent reduction of cell viability in
comparison with controls. The highest cytotoxicity wasportrayed by 80 μM homocysteine which produced 80%
of cell death after 5 days of incubation [9]. A significant
reduction of cell viability to 35% was also observed after
5 days of incubation with 40 μM homocysteine. Cell
exposure to homocysteine for a period of 3 days did not
induce any significant change in Reactive Oxygen Species
(ROS) levels, but incubation with homocysteine for 5 days
resulted in a 4.4-fold increase in ROS production [9].
Homocysteine notably triggered significant levels of geno-
toxic stress which was indicated by the assessment of
DNA fragmentation by Comet assay. But the levels of gen-
otoxic stress was significant only after a longer time of
exposure, as shown by the number of Comet positive cells,
which was significantly increased only after 5 days of incu-
bation with homocysteine [9]. Bax and Bcl-2 mRNA levels
in cells showed an increase by two-fold and 14-fold, re-
spectively, in the case of 5 days exposure to homocysteine
[9]. A time-dependent effect of homocysteine was also
evident. The mRNA levels for the cyclins D1, E1, and A1
were increased by two-fold, six-fold, and five-fold, respect-
ively, in cells exposed to homocysteine for 3 days, but the
mRNA levels in case of cyclin B1 were not affected in the
3 day period [9]. The mRNA levels of all cyclins returned
to the basal levels after 5 days of incubation with homo-
cysteine. A decrease in both mRNA and protein level, of
p21, another key protein regulator of DNA damage in-
duced cell death, was noted after 3 days of incubation with
homocysteine, followed by a dramatic p21 up-regulation
and protein synthesis at 5 days . Further down the time-
line, a significant upregulation of p16 was observed, con-
comitantly with the reduction by 35% of phosphorylated
pRB [9]. These proteins are check-point regulators of
G1-S phase progression through the inhibition of cyclin
D-cdk4 complex and the direct binding and sequestration
of the transcription factor E2F, respectively [9]. Therefore,
this indicates the arrest of cell cycle at G1 phase [9]. The
results suggest that prolonged exposure to mildly elevated
homocysteine concentrations triggers oxidative and geno-
toxic stress in neuronal-like cells [9].
A)The effect of homocysteine on the brain:
By adulthood, the folate related enzymes involved in
purine and pyrimidine synthesis, decline almost tenfold.
Hence, this leads us to believe that the provision of methyl
groups for SAM and methylation reactions coupled with
recycling of homocysteine through methionine synthase
may be dominant function of adult brain folate metabolism
[11]. The brain has a limited capacity for homocysteine
metabolism. Folate plays an important role in the brain so
a crucial mechanism is in play to protect the brain from
folate deficiency. The level of 5 tetrahydrofolate in the
cerebrospinal fluid is 3 times that of the plasma level
and there exists an active process to maintain it [11].
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(neural tissue) that is capable of converting homocyst-
eine to methionine. Cobalamin is a cofactor (hence es-
sential) [11].
The brain tissue utilizes three mechanisms to maintain
a low level of homocysteine [11]:
1) Efficient recycling through cobalamin dependent
methionine synthase (given an adequate supply of
cobalamine and folate),
2) Catabolism through cystathione beta synthase to
cystathione a non-noxious product,
3) Export to external circulation [11].
In the brain and elsewhere disruption of homocysteine
metabolism may result from nutritional imbalance, genetic
defects or as a result of drug therapy [11].
B) The direct effect of homocysteine on the nervous
system:
The action of homocysteine as a neurotransmitter:
homocysteine and its related compounds may have a
role as an excitatory agonist on the NMDA subtype of
glutamate receptors and recent evidence also points to
the involvement of NMDA modulatory sites [11]. It has
also been shown that homocysteine, besides acting as a
partial agonist at glutamate receptors also acts as a par-
tial antagonist of glycine co-agonist site of the NMDA
receptor [11]. In the presence of normal glycine levels and
normal physiological conditions homocysteine does not
cause toxicity below millimolar concentrations. However
in case of a head trauma or stroke, there is an elevation in
glycine levels in which instance the neurotoxic effect of
homocysteine as an agonist outweighs its neuroprotective
antagonist effect. This may cause neuronal damage via
calcium ion influx or free radical generation [11].
One evaluative experiment to discover the direct effect
of homocysteine on the central nervous system involved
local application of homocysteine by two different
methods of drug delivery to the central nervous system of
rats- pressure ejection and ionophoresis [12]. Extracellular
recordings were taken from neurons of cerebral cortex,
cerebellum and midbrain. The recordings after either
method of administration portrayed a dose-dependent
increase in neuronal activity by D, L-homocysteine and
L-glutamate in 67% of cells tested with both drugs. The
similarity in the dose required of D,L-homocysteine and
L-Glutamate, points out that D,L-homocysteine seems to
be as potent as the latter. This data indicates that homo-
cysteine seems to have an excitatory action on neurons,
and this finding may account for neurological symptoms
associated with disorders of amino acid metabolism [12].
Some studies also suggest that elevated homocysteinelevels may be associated with alterations in mental health
such as cognitive impairment, dementia, depression,
Alzheimer’s and Parkinson’s disease [2,11].
Homocysteine and cardiovascular disease
Cardiovascular diseases (CVD) as the name suggests,
comprise of diseases of the heart and blood vessels
[13]. Cardiovascular disease is believed to account for
one third of all deaths worldwide, and the prevalence is
still on the rise [13]. CVD is among the diseases with
multiple contributing factors, hence making it difficult
to pinpoint a particular factor alone. The main factor
that is of relevance to this study is homocysteine. Cor-
onary artery disease is the narrowing or blockage of the
arteries and vessels that supply oxygen and nutrients to
the heart [10]. The severity of coronary artery disease is
classified as single vessel, double vessels and triple ves-
sels disease using the Gensini scoring system [10].
Homocysteine has been recognized as a risk factor as
early as 1990s, for the presence of atherosclerotic vascu-
lar disease and hypercoagulability states [10]. Subgroup
analyses conducted in a study also showed that elevated
homocysteine was associated with higher risk of coron-
ary artery disease in patients with chronic renal dys-
function [14].
Researchers have long debated the extent to which
homocysteine should be considered as a risk factor for
cardiovascular diseases, since according to some, only 50%
of CVD can be explained by “classical” risk factors, and
they say that “new” risk factors could significantly boost
the CVD predictive power [2]. But this has been widely
criticized and there are other authors who show that up to
three quarters of coronary heart disease (CHD) events, if
not more, could be attributed to “classical” risk factors [2].
For the purpose of use as a screening tool, a risk factor
should be strongly and causally associated with the target
disease, and many authors doubt whether such a relation-
ship between homocysteine and CVD exists [2].
The Framingham risk score (FRS), known as an import-
ant instrument in predicting coronary artery disease in pa-
tients with traditional risk factors, such as dyslipidaemia,
hypertension, diabetes mellitus (DM), and smoking, seems
to have underestimated the coronary artery disease risk in
individuals with high homocysteine plasmatic levels [15].
Research has indicated towards a relationship between
moderately elevated homocysteine levels and the risk of
CVD (coronary, heart, cerebrovascular and peripheral
artery diseases) [2]. The homozygous mutation of C‚S can
cause severe hyperhomocysteinemia where homocysteine
concentration is up to 40-fold of the normal levels. This
disease occurs in approximately 1 of 100,000 live births
[2]. When untreated, a vascular event (stroke, myocar-
dial infarction, other thromboembolic complication) oc-
curs in about half of these patients before the age of 30
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hyperhomocysteinemia is due to homozygous mutations
of MTHFR. People with these mutations have been
noted to have premature cardiovascular diseases [2]. But
a large meta-analysis showed the lack of statistically
significant association between MTHFR mutations and
coronary heart disease except in Middle East and Japan,
where it portrayed statistical significance [2].
Homocysteine is known as an independent risk factor
for atherosclerosis [16]. Arteriosclerosis is defined as a
continuous inflammatory damage to the arterial intima
with increased permeability to plasma, deposition of
plasma lipids in plaques and fibrosis and calcification of
plaques [15]. The correlation between hyperhomocystei-
nemia and atherosclerotic disease was first proposed
more than 40 years ago. It was first identified by
McCully in 1969. Atherosclerosis is the most common
pathological process that leads to cardiovascular diseases
such as myocardial infarction (MI), heart failure, stroke
and claudication [13]. Several cross-sectional and case
control studies have pointed towards a clear correlation
between total serum homocysteine and the incidence of
coronary, carotid, and peripheral vascular disease [17].
On the contrary, a systemic review of 12 randomized
controlled trials on 47,429 subjects was carried out to
discover the effectiveness of homocysteine lowering
interventions. Unfortunately, homocysteine lowering
interventions did not show any significant effect on
myocardial infarction, stroke or death by any cause when
compared to a placebo [17]. Homocysteine can mediate
the formation of cardiovascular disease by several differ-
ent mechanisms such as its adverse effects on vascular
endothelium and smooth muscle cells with resultant
alterations in subclinical arterial structure and function
[18]. Some of the presumed mechanisms of these effects
include an increase in proliferation of vascular smooth
muscle cells, endothelial dysfunction, oxidative damage,
an increase is synthesis of collagen and deterioration of
arterial wall elastic material [18]. Examination of the
effect of homocysteine on CRP expression and investiga-
tion on the related mechanism in vascular smooth
muscle cells (VSMCs) revealed that homocysteine
significantly induced mRNA and protein expressions of
CRP in VSMCs both in vitro and in vivo [16]. Homo-
cysteine augmented NR1 subunit (of N-methyl-D-aspar-
tate receptor (NMDAr)) expression, while MK-801
reduced homocysteine induced CRP expression in
VSMCs. The study demonstrated that homocysteine is
capable of initiating an inflammatory response in vascu-
lar smooth muscle cells by stimulating CRP production,
which is mediated through NMDAr-ROS-ERK1/2/p38-
NF-κB signal pathway. These findings provided new
evidence for a role of homocysteine in pathogenesis of
atherosclerosis [16].Using 70 participants (70 patients undergoing coronary
angiography at Kasturba Hospital, Manipal University)
Shenov et al. [10] showed that homocysteine is implicated
as an early atherosclerotic promoter. Fasting serum homo-
cysteine levels in CAD (Coronary artery disease) patients
were significantly higher than patients without coronary
artery disease (p < 0.001) [10]. Also homocysteine levels
correlated significantly with increasing severity of coron-
ary artery disease (p < 0.001). According to this paper, the
most common and plausible mechanism for increased risk
of CAD are endothelial dysfunction thought to occur
primarily from changes in vascular endothelial compliance
and platelet coagulation changes that promote cardio-
vascular disease [10]. In various in vitro studies, homo-
cysteine was proved to trigger proliferation of vascular
smooth muscle cells. It also has role in increasing the
activity of HMG Co A reductase which in turn increases
cholesterol synthesis [10]. An increased cholesterol level
promotes atherosclerosis and hence it is a risk factor for
CAD. Serum levels of homocysteine were found to be
significantly higher in CAD than in non CAD subjects.
Increased serum homocysteine levels positively correlated
with severity of CAD [10]. But the authors assert too that
there is a correlation between homocysteine and coronary
artery disease, despite the fact that every research, includ-
ing this one, has its limitations. Carotid intima-media
thickness (IMT) is a well-accepted non-invasive marker of
subclinical atherosclerosis [19]. The role of homocysteine
in endothelial dysfunction is thought to be mediated by
mechanisms including oxidative stress, nuclear factor-kb
(NF-kb) activation, inflammation, and inhibition of endo-
thelial nitric oxide synthase (eNOS) [19]. While several
observational studies have reported weak positive associa-
tions between total homocysteine concentration and
carotid IMT in the non-diabetic population, few cross-
sectional studies address this association in the context of
diabetes mellitus [19]. The following study observed the
correlation in the case of diabetic patients. Although the
data failed to include a control group without type 1 dia-
betes, in 599 Type 1 diabetic patients from DCCT/EDIC
cohort, plasma total homocysteine levels were similar to
those established for the general population, and corre-
lated with numerous demographic and clinical parameters
[19]. In multivariate analyses, significant correlations were
maintained for age, diastolic blood pressure, and renal
function. Plasma total homocysteine levels also correlated
with common and internal carotid IMT measurements
obtained approximately one and seven years later, but did
not correlate with IMT progression as defined by the
difference between these two determinations [19].
Investigators have reported a significant association of
serum homocysteine concentration with different indices
of arterial stiffness such as pulse pressure and aortic
stiffness as assessed by carotid-femoral Pulse Wave
Ganguly and Alam Nutrition Journal 2015, 14:6 Page 6 of 10
http://www.nutritionj.com/content/14/1/6Velocity (PWV) in the general population [18]. The
carotid-femoral PWV was found to be significantly higher
in the high homocysteine group than in the normal homo-
cysteine group (P = 0.01), however there was no difference
in carotid-radial PWV between the high homocysteine
group and the normal homocysteine group [18]. Linear
regression analysis revealed that homocysteine levels were
significantly related to carotid- femoral PWV (P < 0.001)
whereas no association was found with carotid-radial
PWV [18].
The possible mechanisms explaining the relationship
between hyperhomocysteinemia and aortic stiffness are
not yet fully well established. Main hypotheses based on
this investigation are that homocysteine plays a potential
role in remodelling of the arterial wall leading to vascular
damage [18]. This study as well as the one preceding it
also stated that elevated homocysteine levels may have
enhanced oxidative stress and inflammation of vascular
endothelial cells and reduced the production and bioavail-
ability of nitric oxide (a strong relaxing factor) by the
endothelium [18]. There is also a strong evidence that
oxidation is part of the mechanism attributed to increased
homocysteine and atherosclerosis [10]. Thus we see a
common belief across many papers that an inflammatory
response could be in play.
In an experimental study on mini pigs, mild hyperho-
mocysteinemia was found to cause an arterial, site-
dependent deterioration of the elastic structure involving
metalloproteinase- related elastolysis [18].
Hyperhomocysteinemia has also been shown to be asso-
ciated with a higher risk of venous thrombosis [2]. In-
creased homocysteine level has shown a predilection
towards promotion of platelet adhesion to endothelial
cells and has also been associated with higher levels of
prothrombotic factors for example, β-thromboglobulin,
tissue plasminogen activator and factor VIIc [18]. These
lead to the augmentation of thrombus formation. In
addition, it is possible that enhanced arterial stiffness in hy-
perhomocysteinemia might be attributed to homocysteine
related LDL atherogenesis, like small particle size of LDL
and its oxidative modification [18]. According to a research
by Xie et al. [20] where RBCs from healthy adults were
treated with Homocysteine (8, 20, 80, 200, 800 μmol/L) for
24 hours, homocysteine treatment dose dependently
enhanced phosphatidylserine exposure and conse-
quently the pro-coagulant activity of RBCs. Homocyst-
eine also elevated the formation of pro-coagulant red
blood cell-derived micro-particles, with statistical sig-
nificance at 800 μmol/L of homocysteine [20]. In vitro
studies indicate that homocysteine may have a harmful
effect on endothelial cells, increasing coagulation, and
proliferation of smooth muscle cells. However, homo-
cysteine doses given in many in vitro studies far exceed
pathological homocysteine levels in humans [2]. Thishas to be duly noted in all the future research carried
out in this field and proper adjustment is a dire neces-
sity to get appropriate and comparable results.
A separate study [17] involving the analysis of men aged
65 years or older, carotid RI (Resistive Index) has shown a
significant degree of association with homocysteine. The
data utilised carotid RI as a surrogate marker of cerebral
peripheral artery resistance and pointed out a significant
association between the index and homocysteine levels in
elderly male patients with essential hypertension [17]. This
indicates that increased serum homocysteine may be a
marker of an increase in RI particularly in elderly patients
with a greater risk of stroke [17]. Despite these evidences
the fact that the subjects of this research were aged 65 and
older, should be taken under consideration during specu-
lation in terms of age related factor.
If we add both the genetic as well as nutritional factors,
we may have another contributing factor at hand. Epigen-
etic directive of cardiovascular development and cardiovas-
cular stem cell biology may be related to the cardiovascular
disease predilection [5]. Nutrition and environmental ex-
posures in utero or during periods of famine or any such
critical periods in life, can cause epigenetic alterations in
the expression of genes that contribute to disease risk of
atherosclerosis, hypertension etc. later in life [5]. This out-
come to some extent may be a result of dietary deficiency
of folate, vitamin B12 or choline (a betaine precursor
necessary for folate-independent methylation of homocyst-
eine) since these are essential for methylation reactions
that may epigenetically direct gene expression [5]. But in
light of this, we do need to realize that folate supplementa-
tion is a common practice at present for pregnant women
especially in developed countries, whereas cardiovascular
diseases are more common in the developed world as
opposed to the developing world.
Although it may be of lesser significance, we cannot
completely overshadow this factor. Apart from being part
of the antioxidant defence system, some vitamins also play
a role as enzyme cofactors [13]. Vitamin B6, B12 and folic
acid are essential cofactors in homocysteine-methionine
metabolism. Therefore low vitamin B availability (B6, B12
and folic acid) leads to impaired re-methylation of homo-
cysteine to methionine and thus to homocysteine accumu-
lation [13]. Increased homocysteine levels were found to
be associated with arteriosclerotic outcomes and risk of
stroke in elderly individuals, and are considered as an
independent risk marker for cardiovascular diseases [13].
However, lowering homocysteine levels by B-vitamin
supplementation failed to demonstrate beneficial effects in
cardiovascular diseases and this has been proven to be
true in many other research works [13]. In addition, B
vitamins were shown to reduce homocysteine without
improving endothelial dysfunction or hypercoagulability
[2]. Recent data also seem to indicate that homocysteine
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associated with immune activation [13]. The association
between cardiovascular diseases and homocysteine may
result from deficiency of B vitamins or it may only alter
vascular reactivity when folate is simultaneously low [2].
On the contrary, folate is associated with alteration in
vascular reactivity without homocysteine concentration
changes [2].
It is a universal truth that high blood pressure or
hypertension leads to cardiovascular diseases. There are
numerous factors contributing towards the development
of hypertension, but the association of homocysteine
with blood pressure deserves attention because blood
pressure may mediate part of the cardio toxic effect of
homocysteine [21]. A causal link exists between homo-
cysteine and blood pressure and it is reinforced by experi-
mental and animal studies that have reported a rise in
blood pressure as a consequence of induced hyperhomo-
cysteinemia [21]. Homocysteine may elevate blood pres-
sure through numerous mechanisms such as its effect on
vascular endothelial integrity [21]. Homocysteine adminis-
tration has shown to cause direct endothelial cell injury
in vitro and in animals, as stated before. Homocysteine
induced oxidative stress to endothelium and reduced
available nitric oxide (a potent vasodilator) in cell culture
studies [21]. Observations in humans showed impairment
of endothelium-dependent vasodilation in temporary or
chronic hyperhomocysteinemia [21].
Homocysteine has been positively associated with both
diastolic and systolic blood pressure. In case of homocyst-
eine concentration increase of 5 μmol/L (about 1 SD),Figure 2 Norepinephrine concentration (nmol/L) in paraventricular nudiastolic and systolic blood pressure in men increased by
0.5 and 0.7 mmHg, respectively [21]. In case of women,
the correlation of homocysteine and blood pressure was
stronger, with 0.7 and 1.2 mmHg increase in diastolic and
systolic blood pressure, respectively [21].
To allow for nonlinearity, homocysteine was categorized
into quintiles: The trend in the risk of hypertension with
increasing homocysteine quintiles was significant only in
women (p for trend = 0.0001) [21]. The homocysteine-
cardiovascular disease association was slightly strength-
ened in women, but when the highest and the lowest
quintiles of homocysteine were compared, risk of hyper-
tension showed a threefold increase and a twofold increase
in women and men respectively [21]. The correlation of
homocysteine with prevalent cardiovascular disease has
been examined with and without adjusting for blood
pressure. Upon omission of blood pressure, the associ-
ation was slightly strengthened in women, but there was
little or no change in case of men [21].
An article originally published in Polish on Endothelial
dysfunction in patients with primary hypertension and
hyperhomocysteinemia had some important content. It
stated the wide acceptance of the fact that endothelial
dysfunction happens to be the basis of the development
of cardiovascular diseases, including hypertension [22].
Endothelial dysfunction in the form of impaired vascular
expansion is the major concern with regard to hyperten-
sion [22]. Along with the effects of hyperhomocysteine-
mia mentioned before, this study indicates that it
adversely affects the biosynthesis and function of vaso-
dilator factors in the vascular wall, which in turncleus. Mean value of 6 experiments (*p value < 0.05).
Figure 3 Norepinephrine concentration (nmol/L) in paraventricular nucleus following homocysteine (20 μM) infusion. The values are
mean of 6 experiments. *p < 0.05.
Table 1 Effect of homocysteine (20 μM) infusion on
cardiac contractility
Cardiac contractility dP/dt (mmHg/sec)
Control SHR
1622 ± 120 1056 ± 182*
Results are means ± SE of 6 experiments. Homocysteine was infused through
microdialysis probe in paraventricular nucleus and then cardiac contractility
was measured through a Miller catheter.
*P < 0.05.
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intense myocyte proliferation and migration, and impair-
ment of production of extracellular matrix components
[22]. As mentioned earlier, high levels of homocysteine
and its derivatives add to the process of modification of
LDL and HDL particles, inflammation, coagulation dis-
orders as well as fibrinolysis [22]. Hyperhomocysteine-
mia may lead to biochemical effects on endothelium and
cause damage to endothelial cells, diastolic dysfunction of
vessels and reduction of flexibility due to its influence on
vascular wall remodelling [22]. These mechanisms may
lead to an increase in blood pressure and strengthen the
development of hypertension and damage body organs in
patients with this disease [22].
The question therefore exists if homocysteine is a
biomarker or a risk factor? Current guidelines have not
classified homocysteine as cardiovascular disease risk
stratification. The analyses by Veeranna et al. [14] pro-
spectively validated and showed the incremental value
of homocysteine level in predicting adverse cardiovas-
cular disease events beyond the FRS. Therefore this
paper states that homocysteine fulfils the criteria to
classify it as a “novel” marker [14]. Although lowering
homocysteine levels in individuals with pre-existing
cardiovascular disease has not shown any benefit, medi-
cations as part of a primary prevention strategy need to
be evaluated further for confirmation [14]. Therefore, it
seems unfair to underestimate the utility of homocyst-
eine in cardiovascular disease risk prediction solely
because interventions to lower plasma homocysteine
levels have not shown a favourable outcome regarding
the risk of cardiovascular disease incidence [14]. Yet
there is always room for more research to validatehomocysteine as a risk factor and this is absolutely
necessary for the sake of solid evidence.
On the other hand, such issue might be alarming. Some
recent studies suggest that homocysteine levels may
increase secondary to the occurrence of a cardiovascular
disease and/or due to the presence of atherosclerosis [2].
Subjects with reduced renal function showed elevated
homocysteine concentrations, which suggested that vascu-
lar disease may impair renal function, in turn leading to
hyperhomocysteinemia [2]. But other findings showed that
hyperhomocysteinemia is a predictor of cardiovascular
disease in patients with renal failure as well as chronic
stable renal transplant recipients independently of renal
function and this is contradictory to the assumption that
hyperhomocysteinemia is caused by renal dysfunction [2].
Even though it is possible that the abundance of
published studies that show a positive correlation may
reflect publication bias it is also likely that the negative
studies are false negatives due to a lack of methodo-
logical or statistical power or random error [4]. A sys-
tematic review of studies with the same types of patients
and controls and the same methods and outcome events
may contribute towards a more accurate estimate of the
Ganguly and Alam Nutrition Journal 2015, 14:6 Page 9 of 10
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Furthermore, as discussed previously, the numerous
positive results of retrospective studies may have been a
result of consistent bias since homocysteine levels were
usually measured after the acute vascular event and that
could be the reason behind higher levels of homocyst-
eine [4]. This is quite possible, since it has been noted to
be an issue in most papers and has been speculated in
many cases.
In an effort to see a cause and effect relationship, we
carried out experiments in control and 10 weeks spontan-
eously hypertensive (SHR) rats. The rats were anesthetized
and a microdialysis probe was inserted in paraventricular
nucleus. The fluid was then aspirated for catecholamine
estimation. Figure 2 shows that catecholamine concentra-
tion was higher in SHR rats. Once the homocysteine was
infused through this probe, the level was significantly
higher in SHR rats as compared to control animals
(Figure 3). The SHR animals showed depressed cardiac
contractility. The Table 1 shows the ventricular dP/dt in
control and stroke prone SHR rats; the values are signifi-
cantly depressed in experimental rats. Our results are con-
sistent with a view that homocysteine through the release
of catecholamines can produce detrimental effect in brain
and cardiovascular system.
Conclusion
The published literature indicates that homocysteine is
an independent cardiovascular disease risk factor modifi-
able by nutrition and exercise. However, it is now widely
accepted that food sources alone cannot consistently
supply the levels of nutrients necessary to sustain opti-
mal homocysteine metabolism. In fact, emerging studies
are uncovering novel nutritional strategies for lowering
high homocysteine levels offering new possibilities for
preventing cardiovascular disease.
The speculation of this peculiar correlation continues
to contribute to the perplexity of the scientific society.
Though most research work suggests a relationship, yet
there seems to be other evidence that still prevents its
inclusion as a biomarker. With every ten steps forward,
we might have to face a step or two backward, but this
should only further increase the enthusiasm of research
in this field. This field definitely needs more research
input until a definitive proof is available to cast off any
shadow of doubt regarding the correlation between
homocysteine and cardiovascular disease. Nevertheless,
the present review should provide some insight into the
role of homocysteine in the development of cardiovascu-
lar disease summarizing both central and peripheral
effects of homocysteine. The authors feel that it is
necessary to combat the ill effects of hyperhomocysteine-
mia as it has a pivotal influence on the pathology of the
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